GSK has announced the publication of detailed results from a randomised phase III study (ZOE-70) of its investigational shingles vaccine, Shingrix, showing high efficacy in adults aged 70 years and older that is maintained for at least four years
The results were published in the New England Journal of Medicine(NEJM). The study, from which headline results were reported in October 2015, showed that the two-dose candidate shingles vaccine had 90% efficacy (95% confidence interval: 84-94%) compared to placebo in people over 70 years old.
NEWS
